Related Experiment Video
Updated: Aug 30, 2026
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Peptide targeted imaging of cancer
Georg Riccabona1, Clemens Decristoforo
1Department of Nuclear Medicine, University of Innsbruck, Austria. georg.riccabona@uibk.ac.at
Abstract:
After the discovery of several specific peptide receptors in a variety of cancer types more than 10 years ago, radiolabeled peptide analogs with adequate stability, receptor binding properties, and biokinetic behavior were introduced for imaging of neuroendocrine tumors, several adenocarcinomas, lymphoma, and melanoma. Although initially 123I or 111In were used for labeling, recent efforts have also concentrated on 99mTc or PET-radionuclides (18F,68Ga), as they result in better image resolution with lower radiation dose to patients. Scintigraphy with labeled somatostatin analogs (99mTc, 111In,18F,68Ga), with 123I-labeled vasoactive intestinal peptide, and recently 99mTc-bombesin/GRP-or-111In gastrin analogs, have shown a mean sensitivity of greater than 85% to localize deposits of tumors, with appropriate receptor expression frequently scarcely visible with other imaging procedures. Moreover, these observations introduced peptide-targeted metabolic radiotherapy for metastatic cancers. This development has produced a considerable amount of preclinical studies to broaden the impact of labeled peptide ligands on the management of cancer.
Insights
Radiolabeled peptide analogs are effective for imaging various cancers, including neuroendocrine tumors and melanoma. Newer radiotracers offer improved imaging resolution and lower patient radiation doses, aiding in tumor localization and treatment planning.
Area of Science:
- Nuclear medicine
- Oncology
- Radiopharmaceutical chemistry
Background:
- Specific peptide receptors are key targets in various cancers.
- Radiolabeled peptide analogs have been developed for tumor imaging.
- Early radiolabels (123I, 111In) have been superseded by improved options.
Purpose of the Study:
- To review the application of radiolabeled peptide analogs in cancer imaging.
- To highlight advancements in radiotracer development for improved diagnostics.
- To discuss the role of peptide-based imaging in guiding cancer therapy.
Main Methods:
- Utilizing radiolabeled peptide analogs targeting specific cancer receptors.
- Employing various radioisotopes including 99mTc, 18F, and 68Ga for labeling.
- Performing scintigraphy and other imaging procedures for tumor localization.
Main Results:
- Peptide receptor imaging demonstrates high sensitivity (>85%) for localizing tumors.
- Advanced radiotracers (99mTc, 18F, 68Ga) offer better image resolution and reduced radiation dose.
- Peptide-targeted imaging facilitates the identification of tumors with specific receptor expression.
Conclusions:
- Radiolabeled peptide analogs are valuable tools for diagnosing and staging various cancers.
- The development of novel radiotracers enhances diagnostic accuracy and patient safety.
- Peptide-based imaging is crucial for personalized cancer management and targeted radiotherapy.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:25Imaging Studies II: Positron Emission Tomography and Scintigraphy
Fundamental Principles of PET
01:29Positron Emission Tomography
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body being...